Table 4.
Baseline characteristics and disease severity of COVID-19 patients complicated with hypertension after propensity score matching.
| Parameters | Overall (n=124) | ACEIs/ARBs (n=62) | Non-ACEIs/ARBs (n=62) | P value |
|---|---|---|---|---|
| Age (years), median (IQR) | 68.00 (59.25–75.00) | 68.50 (58.88–76.00) | 67.00 (59.75–74.25) | 0.725 |
| Male sex, n (%) | 63 (50.81) | 33 (53.23) | 30 (48.39) | 0.590 |
| BMI, median (IQR) | 24.09 (21.97–25.95) | 23.98 (21.66–26.10) | 24.11 (22.15–25.36) | 0.958 |
| Vital signs on admission | ||||
| Body temperature (°C), median (IQR) | 36.50 (36.20–36.70) | 36.50 (36.20–36.73) | 36.50 (36.30–36.70) | 0.418 |
| SpO2 (%), median (IQR) | 97.00 (96.00–98.00) | 97.00 (96.00–98.00) | 97.00 (96.00–98.00) | 0.974 |
| SBP (mmHg), median (IQR) | 142.50 (130.00–150.75) | 143.00 (128.00–151.00) | 140.50 (130.00–149.00) | 0.774 |
| DBP (mmHg), median (IQR) | 84.50 (77.00–92.75) | 83.50 (78.00–92.25) | 86.50 (74.25–93.00) | 0.992 |
| HR, median (IQR) | 86.00 (80.00–94.00) | 85.50 (77.75–95.00) | 86.50 (80.00–94.25) | 0.979 |
| RR, median (IQR) | 20.00 (18.00–20.00) | 20.00 (18.00–20.25) | 20.00 (18.00–20.25) | 0.932 |
| 7-categorical ordinal scale on admission | ||||
| ≤3, n (%) | 15 (12.10) | 9 (14.52) | 6 (9.68) | 0.409 |
| >3, n (%) | 109 (87.90) | 53 (85.48) | 56 (90.32) | 0.409 |
| Classification on admission | ||||
| Mild cases, n (%) | 84 (67.74) | 42 (67.74) | 42 (67.74) | 1.000 |
| Severe cases, n (%) | 40 (32.26) | 20 (32.26) | 20 (32.26) | 1.000 |
| Other comorbidities, n (%) | 91 (73.39) | 44 (70.97) | 47 (75.81) | 0.542 |
| Laboratory test on admission | ||||
| K+ (mmol/L), median (IQR) | 4.10 (3.82–4.41) | 4.09 (3.81–4.39) | 4.11 (3.82–4.41) | 0.585 |
| Na+ (mmol/L), median (IQR) | 139.80 (138.00–141.30) | 140.00 (138.30–141.90) | 139.30 (137.70–140.93) | 0.220 |
| Cl− (mmol/L), median (IQR) | 104.00 (101.83–105.98) | 104.00 (102.33–106.05) | 103.85 (101.30–105.93) | 0.621 |
| ALT (U/L), median (IQR) | 21.89 (15.76–34.25) | 22.41 (16.33–35.46) | 20.34 (15.37–33.24) | 0.930 |
| GGT (U/L), median (IQR) | 27.42 (18.96–36.75) | 27.75 (18.68–35.55) | 27.13 (18.99–40.74) | 0.606 |
| TBIL (μmol/L), median (IQR) | 11.22 (9.63–14.07) | 10.76 (9.23–14.33) | 11.37 (9.88–14.06) | 0.616 |
| DBIL (μmol/L), median (IQR) | 2.34 (1.80–3.64) | 2.38 (1.80–3.92) | 2.30 (1.80–3.30) | 0.614 |
| IBIL (μmol/L), median (IQR) | 8.54 (6.87–10.28) | 8.47 (6.58–10.26) | 8.68 (7.51–10.74) | 0.470 |
| CREA (μmol/L), median (IQR) | 60.79 (49.62–74.55) | 60.77 (50.47–79.74) | 60.82 (48.56–73.84) | 0.266 |
| Urea (mmol/L), median (IQR) | 5.19 (4.19–6.30) | 5.12 (4.20–6.18) | 5.39 (4.18–6.31) | 0.565 |
| UA (μmol/L), median (IQR) | 300.71 (242.42–370.07) | 300.76 (239.17–389.15) | 299.24 (247.02–352.76) | 0.744 |
| WBC (109/L), median (IQR) | 6.12 (5.05–7.08) | 5.95 (5.11–6.75) | 6.26 (4.94–7.40) | 0.120 |
| NEUT (109/L), median (IQR) | 3.51 (2.75–4.72) | 3.44 (2.83–4.50) | 3.63 (2.72–4.95) | 0.375 |
| LYMPH (109/L), median (IQR) | 1.54 (1.06–1.99) | 1.68 (1.05–2.00) | 1.48 (1.09–2.00) | 0.436 |
| MONO (109/L), median (IQR) | 0.50 (0.41–0.65) | 0.46 (0.40–0.64) | 0.51 (0.44–0.65) | 0.247 |
| CRP (mg/L), median (IQR) | 0.75 (0.50–5.88) | 0.50 (0.50–4.28) | 1.42 (0.50–8.95) | 0.670 |
| IL-6 (pg/ml), median (IQR) | 2.75 (1.5–6.97) | 2.56 (1.50–5.30) | 3.19 (1.61–8.18) | 0.312 |
ACEIs – angiotensin-converting enzyme inhibitors; ARBs – angiotensin II receptor blockers; IQR – interquartile range; BMI – body mass index; SpO2 – oxyhemoglobin saturation; SBP – systolic blood pressure; DBP – diastolic blood pressure; HR – heart rate; RR – respiratory rate; ALT – alanine aminotransferase; GGT – γ-glutamyl transpeptidase; TBIL – total bilirubin; DBIL – direct bilirubin; IBIL – indirect bilirubin; CREA – creatinine; UA – uric acid; WBC – white blood cells; NEUT – neutrophil; LYMPH – lymphocyte; MONO – monocyte; CRP – C-reactive protein; IL-6 – interleukin-6; SARS-CoV-2 – severe acute respiratory syndrome coronavirus 2.